About Valneva
Valneva is a company based in Lyon (France) founded in 1999. Valneva has raised $113.55 million across 12 funding rounds from investors including Pfizer, European Investment Bank and Bpifrance. The company has 713 employees as of December 31, 2024. Valneva offers products and services including IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine). Valneva operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Lyon, France
- Employees 713 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Valneva Se
-
Annual Revenue
$176.18 M (USD)10.32as on Dec 31, 2024
-
Net Profit
-$12.73 M (USD)87.93as on Dec 31, 2024
-
EBITDA
-$82.04 M (USD)8.71as on Dec 31, 2024
-
Total Equity Funding
$113.55 M (USD)
in 12 rounds
-
Latest Funding Round
$102 M (USD), Post-IPO
Oct 05, 2022
-
Investors
Pfizer
& 7 more
-
Employee Count
713
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Valneva
Valneva is a publicly listed company on the EURONEXT with ticker symbol VLA in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Valneva
Valneva offers a comprehensive portfolio of products and services, including IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine).
Prophylactic vaccine to prevent chikungunya infection.
Vaccine for Lyme disease prevention and protection.
Vaccine targeting Shigella infections.
Prophylactic vaccine against Zika virus.
People of Valneva
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Software Development Team
17 people
Senior Team
11 people
Finance and Accounting
10 people
Head Team
10 people
Product Management Team
9 people
Human Resources and Administration
9 people
Operations Team
8 people
Unlock access to complete
Funding Insights of Valneva
Valneva has successfully raised a total of $113.55M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $102 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Valneva
Valneva has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, European Investment Bank and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
Healthcare investments are targeted by this private equity firm.
|
Locked | Locked | Locked | |
|
Private equity investments in healthcare companies are managed.
|
Locked | Locked | Locked |
Investor details for Valneva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Valneva
Investment portfolio details for Valneva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Valneva
Detailed financials for Valneva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Valneva Comparisons
Peer comparison for Valneva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Valneva
Valneva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
Detailed competitors of Valneva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Valneva
Complete news archive for Valneva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Valneva
Valneva was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Valneva is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Valneva is a funded company, having raised a total of $113.55M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Valneva is 713.
Annual revenue of Valneva is $176.18M as on Dec 31, 2024.
Valneva was founded in 1999 and is headquartered in Lyon, France. Operations are centered in the biotechnology sector, where prophylactic vaccines against infectious diseases are developed. Key candidates include VLA1553, a live-attenuated single-dose vaccine for chikungunya virus, alongside VLA15 targeting Lyme disease, VLA84 for Clostridium difficile prevention, and VLA1601 for Zika virus protection. Research and development efforts are directed toward addressing unmet needs in global health.
Valneva's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
Valneva offers IXCHIQ (Chikungunya Vaccine), VLA15 (Lyme Disease Vaccine), S4V2 (Shigella Vaccine), and VLA1601 (Zika Vaccine).
Yes, Valneva is publicly traded on EURONEXT under the ticker symbol VLA.
Valneva has 8 investors. Key investors include Pfizer, European Investment Bank, Bpifrance, CEPI, and MVM Partners.
The ticker symbol of Valneva is VLA on EURONEXT.